FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

José Herranz

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Infants

Concepts & Ideas

Procedures

Physiology

Drug Resistance

Co-author Network

Publications

TOP 3
María Blanca Sánchez; José L Herranz; Carlos Leno; Rosa Arteaga; Agustín Oterino; Elsa M Valdizán; José M Nicolas; Javier Adín; Mehrdad Shushtarian; Juan A Armijo
UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study.
M Blanca Sánchez; José L Herranz; Carlos Leno; Rosa Arteaga; Agustín Oterino; Elsa M Valdizán; José M Nicolás; Javier Adín; Juan A Armijo
Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
José L Herranz
[Rufinamide. A review of its pharmacokinetic and pharmacodynamic properties].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of José Herranz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: María Blanca Sánchez; José L Herranz; Carlos Leno; Rosa Arteaga; Agustín Oterino; Elsa M Valdizán; José M Nicolas; Javier Adín; Mehrdad Shushtarian; Juan A Armijo
UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study.
Therapeutic drug monitoring 2010;32(2):177-84.
2010: M Blanca Sánchez; José L Herranz; Carlos Leno; Rosa Arteaga; Agustín Oterino; Elsa M Valdizán; José M Nicolás; Javier Adín; Juan A Armijo
Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Seizure : the journal of the British Epilepsy Association 2010;19(2):93-101.
2008: José L Herranz
[Rufinamide. A review of its pharmacokinetic and pharmacodynamic properties].
Revista de neurologia 2008;47(7):369-73.
2007: Juan A Armijo; José L Herranz
[Rational combination therapy in epilepsy. III. Possible associations between antiepileptic drugs].
Revista de neurologia 2007;45(4):236-44.
2007: Juan A Armijo; José L Herranz
[Rational combination therapy in epilepsy. II. Clinical and pharmacological aspects].
Revista de neurologia 2007;45(3):163-73.
2007: Juan A Armijo; José L Herranz
[Rational combination therapy in epilepsy. I. Concepts and foundations].
Revista de neurologia 2007;45(2):95-109.
2007: José L Herranz
[Cognitive repercussion of early-onset epilepsies].
Revista de neurologia 2007;44 Suppl 3():S43-5.
2006: José L Herranz
[Pharmacogenetics, pharmacogenomics and individualised antiepileptic therapy].
Revista de neurologia 2006;43 Suppl 1():S43-9.
2006: José L Herranz; Jose María Prats-Viñas; Jaume Campistol; Jaime Campos-Castelló; Miguel Rufo-Campos; Carlos Casas-Fernández; Rosa Arteaga; Ainhoa García-Ribes; J J Conill; R Domingo-Jiménez
[Effectiveness and safety of levetiracetam in 133 children with medication resistant epileptic seizures].
Revista de neurologia 2006;43(7):393-7.
2006: José L Herranz; Rosa Arteaga; Javier Adín; Juan A Armijo
Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics.
European journal of clinical pharmacology 2006;62(10):805-15.
2006: José L Fernández-Torre; José L Herranz; Marián Martínez-Martínez; Iratxe Maestro; Rosa Arteaga; Javier Barrasa
Early-onset absence epilepsy: clinical and electroencephalographic features in three children.
Brain & development 2006;28(5):311-4.
2005: Ana Argumosa; José L Herranz
[The clinical and economic impact of generic drugs in the treatment of epilepsy].
Revista de neurologia 2005;41(1):45-9.
2005: Juan A Armijo; Noelia Vega-Gil; Mehrdad Shushtarian; Javier Adín; José L Herranz
10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.
Therapeutic drug monitoring 2005;27(2):199-204.
2004: José L Herranz; Ana Argumosa; J Salas-Puig
[Oxcarbazepine in monotherapy in 324 patients with partial seizures (TRINOVA study)].
Revista de neurologia 2004;39(7):601-6.
2004: Javier Adín; M Cruz Gómez; Yolanda Blanco; José L Herranz; Juan A Armijo
Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications.
Therapeutic drug monitoring 2004;26(3):251-7.
2004: Ana Argumosa; José L Herranz
Childhood epilepsy: a critical review of cost-of-illness studies.
Epileptic disorders : international epilepsy journal with videotape 2004;6(1):31-40.
2004: Juan A Armijo; José L Herranz; M A Pena Pardo; Javier Adín
[Intranasal and buccal midazolam in the treatment of acute seizures].
Revista de neurologia 2004;38(5):458-68.
2004: José L Herranz
[Pharmacology in epilepsy. Where are we heading for?].
Revista de neurologia 2004;38(2):167-72.
2003: José L Herranz; Miguel Rufo-Campos; Rosa Arteaga
[Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy].
Revista de neurologia 2003;37(11):1005-8.
2003: José L Herranz
[Levetiracetam in children and adolescents with epilepsy].
Revista de neurologia 2003;37(6):558-60.
2003: José L Herranz
[Severe myoclonic epilepsy in infancy (Dravet's syndrome). Some genetic aspects].
Revista de neurologia 2003;37(1):60-3.
2003: José L Herranz
[Gabapentin: its mechanisms of action in the year 2003].
Revista de neurologia 2003;36(12):1159-65.
2002: BE Caviedes; José L Herranz
[Advances in physiopathology and the treatment of neuropathic pain].
Revista de neurologia 2002;35(11):1037-48.
2002: José L Herranz; Ana Argumosa
[Characteristics and indications of levetiracetam].
Revista de neurologia 2002;35 Suppl 1():S110-6.
2002: José L Herranz; Ana Argumosa
[Characteristics and indications of oxcarbazepine].
Revista de neurologia 2002;35 Suppl 1():S101-9.
2002: Ana Argumosa; José L Herranz; Javier Barrasa; Rosa Arteaga
[Reflex epilepsy from hot water: a new case and review of the literature].
Revista de neurologia 2002;35(4):349-53.
2002: José L Herranz
[Broad clinical prognostic spectrum of Rolandic epilepsy: agreement, disagreement and open questions].
Revista de neurologia 2002;35(1):79-81.
2002: José L Herranz
[Gabapentin in children and adolescents with epilepsy].
Revista de neurologia 2002;34(4):384-7.
2001: S García Calatayud; Rosa Arteaga; José L Herranz
[Microcephaly, bilateral corneal opacity and congenital lobar holoprosencephaly with subsequent development of a rhabdomyosarcoma in a patient exposed to prenatal radiation].
Revista de neurologia 2001;33(10):948-51.
2001: BE Caviedes; José L Herranz
[Use of antiepileptic drugs in non epileptic disorders].
Revista de neurologia 2001;33(3):241-9.
2000: José L Herranz
[Topiramate: a broad spectrum antiepileptic administered to 224 patients with refractory epilepsies].
Revista de neurologia 2000;31(9):822-8.
2000: José L Herranz; Ana Argumosa
[Characteristics of drugs used in the treatment of acute convulsions and convulsive status].
Revista de neurologia 2000;31(8):757-62.
2000: José L Herranz; Ana Argumosa
[Proposals for the treatment of children with West's syndrome].
Revista de neurologia 2000;31(6):578-83.
2000: I de las Cuevas; Rosa Arteaga; A García; José L Herranz
[Hereditary neuropathy with liability to pressure palsies in childhood].
Revista de neurologia 2000;31(1):38-41.
2000: José L Herranz; J M Sol; G Hernández
[Gabapentin used in 559 patients with partial seizures. A multicenter observation study. Spanish Gabapentin Work Group].
Revista de neurologia 2000;30(12):1141-5.
2000: Ana Argumosa; José L Herranz
[Economic aspects of epilepsy].
Revista de neurologia 2000;30 Suppl 1():S154-60.
2000: José L Herranz
[Current data on tiagabine].
Revista de neurologia 2000;30 Suppl 1():S137-41.
2000: José L Herranz
[Current data on topiramate].
Revista de neurologia 2000;30 Suppl 1():S132-6.
2000: José L Herranz
[Current data on gabapentin].
Revista de neurologia 2000;30 Suppl 1():S125-31.
2000: A García; M A Gutiérrez; Javier Barrasa; José L Herranz
Cryptogenic gelastic epilepsy of frontal lobe origin: a paediatric case report.
Seizure : the journal of the British Epilepsy Association 2000;9(4):297-300.
2000: José L Herranz; Ana Argumosa
[Prognosis of epilepsy and withdrawal of treatment: withdrawal of treatment in childhood and adolescents].
Revista de neurologia 2000;30(4):351-5.
2000: Ana Argumosa; José L Herranz
[Economic costs of childhood epilepsy in Spain].
Revista de neurologia 2000;30(2):104-8.
1999: Javier Adín; Rosa Arteaga; José L Herranz; Juan A Armijo
[The use of intravenous valproate].
Revista de neurologia 1999;29(8):744-53.
1999: José L Herranz; Rosa Arteaga
[Long-term efficacy and tolerance of topiramate in 44 children with resistant epilepsy].
Revista de neurologia 1999;28(11):1052-6.
1999: Ana Argumosa; José L Herranz; Rosa Arteaga; Javier Barrasa; L Calles; Juan A Armijo
[Vigabatrin and alterations of the visual field].
Revista de neurologia 1999;28(8):741-5.
1999: Juan A Armijo; Jesús Bravo; Antonio Cuadrado; José L Herranz
Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications.
Therapeutic drug monitoring 1999;21(2):182-90.
1999: BE Caviedes; José L Herranz; Rosa Arteaga; Juan A Armijo
[In children with refractory epilepsy: vigabatrin or lamotrigine?].
Revista de neurologia 1999;28(5):444-8.
1999: José L Herranz; I de las Cuevas
[Epileptic signs of metabolic origin].
Revista de neurologia 1999;28 Suppl 1():S23-8.
1999: José L Herranz
[Factors modifying treatment of adolescents with epilepsy].
Revista de neurologia 1999;28(1):49-53.
1998: José L Herranz
[Tiagabine: recent findings and recommendations for dosage].
Revista de neurologia 1998;27(155):101-3.
1998: José L Herranz
[Suggestions regarding new classification of epileptic seizures].
Revista de neurologia 1998;26(152):598-600.
1998: BE Caviedes; José L Herranz
Seizure recurrence and risk factors after withdrawal of chronic antiepileptic therapy in children.
Seizure : the journal of the British Epilepsy Association 1998;7(2):107-14.
1998: José L Herranz; I de las Cuevas
[Diagnostic focus on the child with myoclonic seizures in isolation or associated with other types of seizures].
Revista de neurologia 1998;26(150):301-7.
1997: Renee Ribacoba; J Salas-Puig; D M Solar; B Otero; José L Herranz
[The efficacy of the valproic acid-ethosuximide combination in the continuous slow point wave syndrome during sleep].
Neurología (Barcelona, Spain) 1997;12(8):335-8.
1997: José L Herranz
[Tiagabine: a GABA-ergic anti-epileptic drug].
Revista de neurologia 1997;25(146):1607-10.
1997: José L Herranz
[Topiramate, a new antiepileptic drug].
Revista de neurologia 1997;25(144):1221-5.
1997: BE Caviedes; José L Herranz
[When and how should the long-term anti-epileptic treatment be stopped].
Revista de neurologia 1997;25(139):372-8.
1996: José L Herranz
[Advantages and disadvantages of new antiepileptic drugs].
Revista de neurologia 1996;24(135):1426-34.
1994: José L Herranz; Rosa Arteaga; Juan A Armijo
[New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
Neurología (Barcelona, Spain) 1994;9(9):410-7.
1993: Rosa Arteaga; José L Herranz; Juan A Armijo
[Basic norms for the utilization of phenytoin by intravenous injection].
Neurología (Barcelona, Spain) 1993;8(6):184-7.
1993: Rosa Arteaga; José L Herranz; Juan A Armijo
Platelet GABA-transaminase in epileptic children: influence of epilepsy and anticonvulsants.
Epilepsy research 1993;14(1):73-85.
1992: Juan A Armijo; Rosa Arteaga; Elsa M Valdizán; José L Herranz
Coadministration of vigabatrin and valproate in children with refractory epilepsy.
Clinical neuropharmacology 1992;15(6):459-69.
1992: Rosa Arteaga; José L Herranz; Elsa M Valdizán; Juan A Armijo
Gamma-vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children.
Epilepsia 1992;33(5):923-31.
1991: José L Herranz; Rosa Arteaga; I N Farr; E Valdizan; D Beaumont; Juan A Armijo
Dose-response study of vigabatrin in children with refractory epilepsy.
Journal of child neurology 1991;Suppl 2():S45-51.
1989: José A Riancho; C del Arco; Rosa Arteaga; José L Herranz; M Albajar; J G Macias
Influence of solar irradiation on vitamin D levels in children on anticonvulsant drugs.
Acta neurologica Scandinavica 1989;79(4):296-9.
1989: Juan A Armijo; José L Herranz
[Toxicity of antiepileptic drugs].
Neurología (Barcelona, Spain) 1989;4(3):88-102.
1989: Juan A Armijo; Rosa Arteaga; R Valiente; José L Herranz
Platelet GABA-aminotransferase in epileptic patients.
International journal of clinical pharmacology research 1989;9(4):283-5.
1988: José L Herranz; Juan A Armijo; Rosa Arteaga
Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children.
Epilepsia 1988;29(6):794-804.
1987: José L Herranz; J L Arce; J Morán; F J Figols; Rosa Arteaga; R Galván
[Mosaic trisomy 9. Report of a new case and delimitation of the clinical syndrome].
Anales españoles de pediatría 1987;26(3):191-6.
1986: Juan A Armijo; José L Herranz; Rosa Arteaga; R Valiente
Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation.
Clinical pharmacokinetics 1986;11(4):323-35.
1985: Juan A Armijo; José L Herranz
[Nomogram for phenobarbital dosage in children].
Anales españoles de pediatría 1985;22(5):418-21.
1984: José L Herranz; Juan A Armijo; Rosa Arteaga
Effectiveness and toxicity of phenobarbital, primidone, and sodium valproate in the prevention of febrile convulsions, controlled by plasma levels.
Epilepsia 1984;25(1):89-95.
1983: José L Herranz; Juan A Armijo
[Neurologic toxicity of desmovin].
Anales españoles de pediatría 1983;18(3):256-8.
1982: José L Herranz; Rosa Arteaga; Juan A Armijo
Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients.
Epilepsia 1982;23(2):203-14.
1981: José L Herranz; E Mazo; R Arteaga; V Hermosa; Alberto Zubizarreta
[Erythrocyte membrane protein in Duchenne muscular dystrophy (author's transl)].
Anales españoles de pediatría 1981;15(5):433-42.
1981: Juan A Armijo; R Valiente; José L Herranz
[Relation between plasma levels of valproic acid alone and its efficacy and toxicity in pediatric patients under chronic treatment].
Archivos de farmacología y toxicología 1981;7(1):49-56.